MedTrace Logo

Biomarker Guided Treatment in DLBCL

NCT04025593 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2020-11-19

No results posted yet for this study

Summary

This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma

Conditions

Interventions

DRUG

Cyclophosphamide

750mg/m2 day 1

DRUG

Rituximab

375mg/m2 day 0

DRUG

Doxorubicin

50mg/m2 day 1

DRUG

Vincristine

1.4mg/m2, max 2mg day 1

DRUG

Prednisone

60mg/m2, max 100mg day 1-5

DRUG

Ibrutinib

420mg/day qd

DRUG

Lenalidomide

25mg day1-10

DRUG

chidamide

20mg day 1,4,8,11

DRUG

decitabine

decitabine 10mg/m2 day-5 to day-1

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2021-07-01
Completion
2023-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04025593 on ClinicalTrials.gov